{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":19,"x_thread":9,"podcast":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05552222\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MajesTEC-7","nct_id":"NCT05552222","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=majestec-7-nct05552222. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MajesTEC-7","arms":[{"description":"Participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.","label":"Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR)","type":"EXPERIMENTAL"},{"description":"Participants will receive talquetamab as SC injection in combination with daratumumab and lenalidomide.","label":"Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR)","type":"EXPERIMENTAL"},{"description":"Participants will receive daratumumab as SC injection with lenalidomide and dexamethasone.","label":"Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2033-10-28","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":1590,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Teclistamab","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Talquetamab","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization to the date of disease progression or death (Up to 09 years)"},{"measure":"12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)","timeFrame":"At Month 12"}],"references":[],"start_date":{"date":"2022-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05552222"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/majestec-7-nct05552222"}